397 related articles for article (PubMed ID: 27680683)
1. Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
Xia T; Konno H; Barber GN
Cancer Res; 2016 Nov; 76(22):6747-6759. PubMed ID: 27680683
[TBL] [Abstract][Full Text] [Related]
2. Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.
de Queiroz NMGP; Xia T; Konno H; Barber GN
Mol Cancer Res; 2019 Apr; 17(4):974-986. PubMed ID: 30587523
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.
Bommareddy PK; Zloza A; Rabkin SD; Kaufman HL
Oncoimmunology; 2019; 8(7):1591875. PubMed ID: 31143509
[TBL] [Abstract][Full Text] [Related]
4. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
5. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
Johnson DB; Puzanov I; Kelley MC
Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
[TBL] [Abstract][Full Text] [Related]
6. Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo.
Schwertner B; Lindner G; Toledo Stauner C; Klapproth E; Magnus C; Rohrhofer A; Gross S; Schuler-Thurner B; Öttl V; Feichtgruber N; Drexler K; Evert K; Krahn MP; Berneburg M; Schmidt B; Schuster P; Haferkamp S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205379
[TBL] [Abstract][Full Text] [Related]
7. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Kohlhapp FJ; Kaufman HL
Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
[TBL] [Abstract][Full Text] [Related]
9. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production.
Konno H; Yamauchi S; Berglund A; Putney RM; Mulé JJ; Barber GN
Oncogene; 2018 Apr; 37(15):2037-2051. PubMed ID: 29367762
[TBL] [Abstract][Full Text] [Related]
10. Talimogene Laherparepvec: First Global Approval.
Greig SL
Drugs; 2016 Jan; 76(1):147-54. PubMed ID: 26620366
[TBL] [Abstract][Full Text] [Related]
11. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R; Hoeller C; Gruter IP; Michielin O
Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
[TBL] [Abstract][Full Text] [Related]
12. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
Hoffner B; Iodice GM; Gasal E
Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
[TBL] [Abstract][Full Text] [Related]
13. Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells.
Ahn J; Xia T; Rabasa Capote A; Betancourt D; Barber GN
Cancer Cell; 2018 May; 33(5):862-873.e5. PubMed ID: 29706455
[TBL] [Abstract][Full Text] [Related]
14. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.
Falahat R; Perez-Villarroel P; Mailloux AW; Zhu G; Pilon-Thomas S; Barber GN; Mulé JJ
Cancer Immunol Res; 2019 Nov; 7(11):1837-1848. PubMed ID: 31462408
[TBL] [Abstract][Full Text] [Related]
15. First Oncolytic Viral Therapy for Melanoma.
Poh A
Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414
[TBL] [Abstract][Full Text] [Related]
16. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
Schierer S; Hesse A; Knippertz I; Kaempgen E; Baur AS; Schuler G; Steinkasserer A; Nettelbeck DM
Int J Cancer; 2012 Apr; 130(7):1682-94. PubMed ID: 21557217
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis.
Xia T; Konno H; Ahn J; Barber GN
Cell Rep; 2016 Jan; 14(2):282-97. PubMed ID: 26748708
[TBL] [Abstract][Full Text] [Related]
18. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
19. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
Cui J; Chen Y; Wang HY; Wang RF
Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
